Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.
Jason Luke, MD, FACP, associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutic Center at the UPMC Hillman Cancer Center, discusses promising clinical research around intratumoral immunotherapy.
There are multiple studies in the area of intratumoral immunotherapy that have the potential to make a large impact in the field, says Luke. One notable trail is a randomized phase III, which is evaluating tilsotolimod with or against ipilimumab (Yervoy) in patients with melanoma. If the trial is positive, it may impact the standard of car, by offering a new option for patients with melanoma who progress on a PD-1 inhibitor.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More